Xbrane Pulls In US Ranibizumab Partner After FDA Disappointment
License Fee Of Up To $45m Agreed, To Be Split Between Xbrane And Stada
Xbrane Biopharma’s recent CRL for its proposed US biosimilar to Lucentis has not prevented the Swedish company from announcing a successor to Bausch + Lomb to partner on the biosimilar’s US marketing and commercialization.
